Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patientsYasuhiro Nakamura, N. Yamazaki, Satoshi Fukushima et al.|Annals of Oncology|2020Cited by 140
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patientsKaori Sakaizawa, Hisashi Uhara, Atsuko Ashida et al.|Journal of Dermatological Science|2015Cited by 120
Systemic therapy for Asian patients with advanced <scp>BRAF V600</scp>‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (<scp>B‐CHECK‐RWD</scp> study)Kenjiro Namikawa, Naoya Yamazaki, Takamichi Ito et al.|Cancer Medicine|2023Cited by 25